Aims & Scope
Genetic Engineering & Biotechnology News (GEN) was the first publication in the field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment and funding growth, and career opportunities. For more than 40 years, GEN has maintained unparalleled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry.
The exclusive features, reporting, and analysis in GEN enable new scientific discoveries, accelerate the pace of research, and drive large-scale funding and investments. A site-wide license enables end users across myriad disciplines to translate research into real-world applications and to understand the impact of the developments driving the future of biotechnology.
GEN coverage includes:
- Drug Discovery
- Assay Development
- Cancer Research
- Cannabis
- Animal Models
- Infectious Diseases
- Cancer Research
- Immunotherapy
- Cell Therapy
- Oncogenes
- Tumor Suppressor
- Genes
- Rational Drug Design
- Monoclonal
- Antibodies
- OMICS
- Sequencing
- Mass Spectrometry and Proteomics
- Spatial Biology
- Metabolomics
- Genomics
- Forensics
- Epigenetics
- Infectious Diseases
- Vaccine Development
- Virology
- COVID-19
- RNA Vaccines
- Genome Editing
- CRISPR
- Agbiotech
- Gene Therapy
- RNA Editing
- Synthetic Biology
- Base Editing
- Translational Medicine
- Liquid Biopsy
- Molecular Diagnostics
- Biomarkers
- Microbiome
- Nanotechnology
- Microfluidics
- Stem Cells
- Bioprocessing
- Bioprocessing 4.0
- Cell Manufacturing
- Gene Therapy
- Manufacturing
- Viral Safety
- Gene Expression
- Glycobiology
- Artificial Intelligence
- Machine Learning
- Big Data
- Informatics
- Neural Networks
- High-performance Computing
Indexing/Abstracting:
- Biotechnology Citation Index®
